Zhu Xinxin, Cai Han, Zhao Ling, Ning Li, Lang Jinghe
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
Department of Obstetrics and Gynecology, Institute for Wound Research, University of Florida, Gainesville, Florida, USA.
Oncotarget. 2017 Aug 4;8(38):64607-64621. doi: 10.18632/oncotarget.19929. eCollection 2017 Sep 8.
Ovarian cancer (OC) is the most lethal gynecological malignancy and is responsible for most gynecological cancer deaths. Apart from conventional surgery, chemotherapy, and radiotherapy, chimeric antigen receptor-modified T (CAR-T) cells as a representative of adoptive cellular immunotherapy have received considerable attention in the research field of cancer treatment. CARs combine antigen specificity and T-cell-activating properties in a single fusion molecule. Several preclinical experiments and clinical trials have confirmed that adoptive cell immunotherapy using typical CAR-engineered T cells for OC is a promising treatment approach with striking clinical efficacy; moreover, the emerging CAR-Ts targeting various antigens also exert great potential. However, such therapies have side effects and toxicities, such as cytokine-associated and "on-target, off-tumor" toxicities. In this review, we systematically detail and highlight the present knowledge of CAR-Ts including the constructions, vectors, clinical applications, development challenges, and solutions of CAR-T-cell therapy for OC. We hope to provide new insight into OC treatment for the future.
卵巢癌（OC）是最致命的妇科恶性肿瘤，导致了大多数妇科癌症死亡。除了传统的手术、化疗和放疗外，作为过继性细胞免疫疗法代表的嵌合抗原受体修饰T（CAR-T）细胞在癌症治疗研究领域受到了广泛关注。嵌合抗原受体在单个融合分子中结合了抗原特异性和T细胞激活特性。多项临床前实验和临床试验证实，使用典型的CAR工程化T细胞对OC进行过继性细胞免疫疗法是一种具有显著临床疗效的、很有前景的治疗方法；此外，新兴的靶向各种抗原的CAR-T细胞也具有巨大潜力。然而，此类疗法存在副作用和毒性，如细胞因子相关毒性和“靶向肿瘤外”毒性。在本综述中，我们系统地详细阐述并突出了目前关于CAR-T细胞的知识，包括其构建、载体、临床应用、发展挑战以及针对OC的CAR-T细胞疗法的解决方案。我们希望为未来的OC治疗提供新的见解。
